Research summary, original research, 2017

Reduction in radiation dose for atrial fibrillation ablation over time: A 12-year single-center experience of 2344 patients

Voskoboinik A, Kalman ES, Savicky Y, Sparks PB, Morton JB, Lee G, et al.. Heart rhythm. 2017

Read the original paper

In plain language

At one center, fluoroscopy time and patient dose for atrial fibrillation ablation fell sharply over 12 years, with lower values when contact force catheters were used. Staff dose was not measured, but less fluoroscopy likely means less exposure for the electrophysiology (EP) team.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients, Electrophysiologists
Size
n = 2,344 procedures
Summary based on
the abstract

What it found

  • Fluoroscopy time for initial pulmonary vein isolation (PVI) fell progressively from 2004-2006 to 2013-2015.

    Key figures: 61 ± 27 minutes (2004-2006) to 17 ± 9 minutes (2013-2015)

  • Absorbed and effective doses for initial PVI fell between 2007-2009 and 2013-2015.

    Key figures: 1365 ± 1369 mGy, 11.3 ± 12.5 mSv (2007-2009) to 304 ± 758 mGy, 5.5 ± 6.7 mSv (2013-2015)

  • Contact force-sensing catheters were associated with shorter fluoroscopy time and lower absorbed dose in PVI-only cases in 2014-2015.

    Key figures: 11 ± 5 vs 21 ± 8 minutes, P <.001; 200 ± 524 vs 470 ± 1326 mGy, P = .004

  • The authors attribute the decline to operator experience, case volume, technology evolution and CF-sensing catheters.

Limits to keep in mind

Single-center observational review of patient dose metrics; staff dose was not measured directly, and the catheter comparison is non-randomized and confounded by time and experience.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.